Erectile dysfunction and antihypertensive therapy: A critical reappraisal

A narrative review claims newer antihypertensives are ED-neutral or better, but cites no new data of its own

Journal: European journal of internal medicine | Published: 2026-04-09 | Type: Journal Article, Review | PMID: 41963149 Authors: Manolis Athanasios J, Kallistratos Manolis S, Koutsaki Maria, Papaioannou Nikolaos (Cardiology Department, METROPOLITAN Hospital, Piraeus, Greece); Doumas Michael (Aristotle University, Thessaloniki, Greece) Funding/COI: Funding not listed; no competing interests declared

Summary

This is a narrative review, not a study with new data, arguing that older antihypertensive drugs (notably beta-blockers and thiazide diuretics) damaged erectile function while newer classes are neutral or even helpful. The abstract doesn't cite a single number — no effect sizes, no prevalence figures, no trial names — so there's nothing here to independently verify from the abstract alone.

Claims

• Erectile dysfunction and hypertension "share a common vascular pathophysiology" (mechanism claim, unquantified)
• Older antihypertensive drug classes "had a significant impact" on erectile function (no effect size given)
• Newer antihypertensive drugs "may exert a neutral or even beneficial effect" on erectile function (hedged, unquantified)
• The authors state they provide "evidence-based recommendations tailored to clinical practice" (recommendations, not new findings)

Study Quality

This is a narrative review, the weakest tier of review methodology — no stated search strategy, no inclusion/exclusion criteria, no quality appraisal of the underlying studies, and no meta-analytic pooling of effect sizes. The abstract offers zero quantitative data (no ORs, no percentages, no sample sizes of the studies it's synthesizing), which means readers have to trust the authors' selection and interpretation of the literature rather than check numbers themselves.

The cardiology-heavy author panel (four of five affiliated with a single hospital's cardiology department) suggests a clinician's-eye synthesis rather than an independent, systematic evidence review. Without the full text, it's impossible to tell whether "recent evidence" refers to RCTs, observational cohorts, or expert opinion.

Red Flags

• No search methodology described (not a systematic or scoping review)
• Zero numbers in the abstract — no effect sizes, sample sizes, or study counts
• "Evidence-based recommendations tailored to clinical practice" is advisory language from a narrative synthesis, not a data-derived conclusion
• Single-institution cardiology group authoring conclusions about a urologic/sexual health outcome
• Funding not listed (unclear if this is an omission or truly unfunded)

Verdict

A narrative review with no quantitative content in its own abstract isn't something to build conclusions on — it's a starting point for finding the primary studies it's actually synthesizing. Worth reading the full text to see which trials it leans on, but the abstract alone gives readers nothing to check its claims against.